objeCtives: To estimate, from a Greek payer perspective, the budget impact of adopting certolizumab pegol (CZP) for the treatment of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic axSpA (nraxSpA). Methods: A budget impact model was locally adapted over a time horizon of 5 years, to estimate the impact of CZP taking shares from adalimumab (ADA), infliximab (IFX), etanercept (ETA), and golimumab (GOL), but not from conventional care (CC) in AS; and ADA but not CC in nr-axSpA. Data from AS and nr-axSpA populations in Greece were combined with data on market shares of available anti-TNFs and associated costs (i.e. medication acquisition and administration, healthcare visits, laboratory and imaging tests) to estimate the budgetary consequences of CZP penetration. Data on the number of axSpA patients were derived from the National Statistical Service, published literature and expert opinion. It was assumed that the share of CZP will increase steadily from 5% in the first year to 13% in the fifth year of analysis in both populations, taking equal shares from the other biologicals. Drug and medical care reimbursement prices are net and reflect 2015 prices. Results: On average, the use of CZP is estimated to decrease the mean annual budget per AS patient by between € 95 to € 176 (0.9%-1.7%). On the other hand, CZP is anticipated to increase the annual budget per nr-axSpA patient by between € 809 to € 827 (8.6% to 8.8%), as it costs slightly more than ADA. For the overall axSpA population, the average annual increase per patient ranges from € 342 to € 372 (3.4% to 3.7%), which is below a reimbursement threshold set by the main health insurance fund. ConClusions: The reimbursement of CZP for the treatment of axSpA patients in Greece will, on aggregate, result in a modest and acceptable increase in the total therapy cost.
PMS33 Budget IMPact analySIS of an etanercePt BIoSIMIlar for the treatMent of all lIcenSed etanercePt IndIcatIonS for adultS In euroPe
Ruff L 1 , Rezk MF 2 , Uhlig T 3 , Gommers JW 2 1 Covance Inc., London, UK, 2 Biogen International GmbH, Zug, Switzerland, 3 Diakonhjemmet Hospital, Oslo, Norway objeCtives: Biologics such as etanercept, can be efficacious in reducing disease activity in their authorised indications, but are considered costly. The objective of this study was to assess future budget-impact of introducing an etanercept biosimilar in the EU5 for all licensed adult indications. Methods: A budget-impact model (BIM) was developed to estimate the impact of potentially introducing an etanercept biosimilar on the healthcare budgets in over a five-year horizon (2016) (2017) (2018) (2019) (2020) from the payer's perspective. Prevalence-based, incidence-based and country-specific model adaptations evaluate the impact of introducing an etanercept biosimilar to a segment of the anti-TNFs market that includes innovator etanercept and adalimumab for rheumatoid arthritis (RA), psoriatic arthritis (PsA) psoriasis (PsO) and ankylosing spondylitis (AS); comparing total costs for scenarios with and without the biosimilar. Patients naïve to biologics, stable on, or failing the first biologic were tracked under a set of conservative assumptions: (1) uptake of 5% to 40% from etanercept to the biosimilar; (2) anti-TNF price erosion of 5% per year; (3) unknown price of etanercept biosimilar -two discount scenarios versus etanercept (10%, 25%) were applied. Results: The hypothetical introduction of an etanercept biosimilar in the biologic treatment setting for scenarios with a 10% or 25% cost reduction compared with innovator etanercept results in projected net budget-savings of (millions): (1) UK € 111-284, (2) France € 35-81, (3) Germany € 76-187, (4) Italy € 46-111 and (5) Spain € 28-65. Such savings, could be used to fund treatment for an additional 3,100 (UK) to 17,130 (Germany) patients with etanercept biosimilar over fiveyears. ConClusions: The introduction of an etanercept biosimilar could represent substantial cost-saving potential for EU5 healthcare systems; budget-impact was sensitive to market uptake-rates and discounts versus etanercept. These savings could be used to treat additional patients with a biosimilar.
PMS34 Budget IMPact analySIS of tocIlIzuMaB VerSuS adalIMuMaB aS a fIrSt lIne (1l) MonotheraPy for the treatMent of PatIentS WIth rheuMatoId arthrItIS (ra) In greece
Argyriou A 1 , Papageorgiou L 1 , Argyropoulos E 1 , Skroumpelos A 2 , Caporis X 1 1 Roche Hellas, Athens, Greece, 2 Roche (Hellas) S.A., Athens, Greece objeCtives: To evaluate and compare the budget impact of tocilizumab intravenous (IV) and adalimumab subcutaneous as a 1L monotherapy for the 6-month treatment of patients with RA, in the Greek healthcare system Methods: A budget impact model was developed to evaluate the cost per response rate of the two therapeutic options. Clinical data were derived from a head-to-head trial (ADACTA) and referred to the efficacy endpoints ACR 70, DAS 28≤ 3.2 and DAS 28< 2.6. Cost and resource utilization data were obtained from official government sources (2014) and included the cost of drugs, consumables, human resources, hospital charges and patient's time (productivity loss). Cost per response for both therapeutic options was estimated for all three clinical endpoints from the hospital, health system and societal objeCtives: To estimate the incremental total and per-patient budget impact of adopting certolizumab pegol (CZP) for the recently indicated treatment of active psoriatic arthritis (PsA) in Greece. Methods: A budget impact model was adapted from a third-party payer perspective (EOPYY) to delineate the financial implications of introducing CZP for the treatment of PsA alongside currently indicated biologic treatments, namely etanercept, infliximab, adalimumab, golimumab, and ustekinumab, over the next 5 years (2014) (2015) (2016) (2017) (2018) . The model framework considered market share scenarios with and without CZP, and directly reimbursed costs of treatment and disease management, applied to the prevalent and eligible Greek patient population. Quarterly treatment discontinuation was geared to enable tracking of patients, so that the model could apply different costs to patients at different stages of treatment. Costs pertaining to drug acquisition, administration and monitoring were included for both the induction and maintenance years of patients' treatment and corresponded to current costing year. Resource unit costs and epidemiological data were retrieved from officially published sources. The measured outcomes were incremental costs per treated patient per year (PTPPY) and total budget impact, calculated by comparing the respective patient and total budget expenditures with and without CZP in the market share mix scenarios. Results: The incremental total and PTPPY costs resulting from the addition of CZP to the original treatment mix were estimated at -€ 2,036,848 (-1.76%) and -€ 859 respectively, over a 5-year time horizon. On average, annual cost-savings of € 407,370 (-1.76%) and € 172 were observed for both outcomes respectively. In each model, yearly cost-savings were yielded and 2018 was the year with the highest total cost-savings for EOPYY (€ 512,296 [-2 .2%]). Cost-savings were driven by reduced drug and administration costs. ConClusions: The inclusion of CZP for active PsA treatment was predicted to be associated with short-and long-term cost-savings in Greece.
PMS30 Budget IMPact analySIS of IMPleMentIng tenderS BetWeen the Branded InflIxIMaB and ItS BIoSIMIlarS In the PuBlIc hoSPItalS of ParIS
Bocquet would generate savings of € 22.8 million and S2 would save € 34.2 million, whereas with S3 the savings would amount to € 7.3 million (€ 4.5 million in gastroenterology, € 2.1 million in rheumatology, € 0.1 in dermatology and € 0.6 in other indications). ConClusions: If the Committee on Medicinal Products (COMED) of AP-HP decides to implement tenders between BRANDED-INFLIX and BIOSIM-INFLIX the savings will be largely dependent on the scope of these tenders. These results could be considered by the COMED in its decision-making process.
PMS31 Budget IMPact analySIS of an etanercePt BIoSIMIlar for the treatMent of rheuMatoId arthrItIS In euroPe
Ruff L 1 , Rezk MF 2 , Uhlig T 3 , Gommers JW 2 1 Covance Inc., London, UK, 2 Biogen International GmbH, Zug, Switzerland, 3 Diakonhjemmet Hospital, Oslo, Norway objeCtives: Rheumatoid arthritis (RA) has considerable impact on physical function and reduces quality of life. Biologics, such as etanercept, can be efficacious in reducing disease activity in their authorised indications. However, these treatment options can be very costly and present economic pressures on healthcare funding. The objective of this study was to assess budget-impact of introducing an etanercept biosimilar in the five largest European countries (EU5). Methods: A budget-impact model (BIM) was developed to estimate the impact of the hypothetical introduction of an etanercept biosimilar on the healthcare budgets in EU5 over a five-year horizon (2016) (2017) (2018) (2019) (2020) from the payer's perspective. Prevalence-based, incidencebased and country-specific model adaptations evaluate the impact of introducing an etanercept biosimilar to a segment of the anti-TNF market that includes innovator etanercept and adalimumab; comparing total costs for scenarios with and without a biosimilar. Patients naïve to biologics, on stable treatment and failing the first biologic were tracked in the model under a set of conservative assumptions: (1) uptake of 5% to 40% (2016-2020 ) from etanercept to the biosimilar; (2) anti-TNF price-erosion of 5% per year; (3) unknown price of etanercept biosimilar -discount scenarios versus etanercept (10%, 25%) were applied. Results: The theoretical introduction of an etanercept biosimilar with a 10%
